Key Stats
- Current price: ~$243
- Q1 2026 revenue: $39.6B, up 23% YoY from $32.1B
- Q1 2026 adjusted EPS: $10.31, down 11% YoY from $11.58
- Q1 2026 EBIT: $1.75B, down 13% YoY from $2.0B
- Medicare Advantage membership growth: ~22% YoY (per transcript)
- 2028 individual MA margin target: at least 3% sustainable margin
- TIKR model price target: ~$706
- Implied upside: ~190% from current price
Humana Stock Posts Revenue Surge, But Margin Pressure Defines the Q1 2026 Story
Humana stock (HUM) reported Q1 2026 revenue of $39.6B, up 23% from $32.1B in the prior-year quarter, driven by a surge in Medicare Advantage membership that expanded the company’s premium base.
Adjusted EPS came in at $10.31, down 11% from $11.58 in Q1 2025, with the decline driven by elevated medical cost trend outpacing plan funding rather than any operational deterioration.
The insurance segment drove the bulk of the revenue expansion, with premium and annuity revenues rising from $30.5B in Q1 2025 to $37.7B in Q1 2026.
Medicare Advantage membership grew approximately 22% year over year, according to President and CEO Jim Rechtin on the Q1 2026 earnings call, with both new and returning members performing in line with internal expectations.
CenterWell added 110,000 patients sequentially in Q1, a 22.5% sequential increase, through organic growth and the recently completed MaxHealth acquisition, according to CenterWell President Dr. Sanjay Shetty on the Q1 2026 earnings call.
Rechtin was direct on the core tension: the gap between Medicare Advantage funding and medical cost trend is wider heading into the 2027 bid cycle than it was a year ago.
Benefit reductions are planned for the 2027 plan year, with management’s stated priority order being: hitting the 2028 target margin of at least 3%, retaining existing members, and growth as a distant third.
Humana raised $1B in junior subordinated notes in March to address 2027 maturities and mitigated over $3B in capital contribution requirements for 2026, according to CFO Celeste Mellet on the Q1 2026 earnings call.
Humana Stock Financials: Revenue Scaling, Operating Margins Under Pressure
The Q1 2026 income statement tells a classic enrollment-driven revenue expansion story with margin compression layered on top, as accelerating membership growth pulls costs up faster than operating leverage can offset.
Total revenues stepped from $32.1B in Q1 2025 to $32.4B in Q2 2025, $32.7B in Q3 2025, $32.5B in Q4 2025, and then accelerated sharply to $39.6B in Q1 2026, a 23.5% year-over-year increase.
Operating income followed a volatile path, moving from $2.0B in Q1 2025 down to $1.2B in Q2 2025, $620M in Q3 2025, a loss of $580M in Q4 2025, and recovering to $1.75B in Q1 2026.
Operating margin compressed from 6.3% in Q1 2025 to 4.4% in Q1 2026, a 185-basis-point decline year over year, even as the sequential rebound from Q4 2025’s negative 1.8% margin is notable.
Policy benefits scaled from $26.5B in Q1 2025 to $33.7B in Q1 2026, reflecting the membership expansion, and management attributed the margin gap to medical cost trend that continues to outpace program funding, a dynamic Rechtin confirmed will require benefit adjustments for 2027.
Mellet noted on the earnings call that operating cost improvement targets for the full year remain on track, with efficiency gains accelerating in corporate functions including finance and HR as outsourcing approaches industry benchmarks.
What Does the Valuation Model Say?
The TIKR model prices Humana stock at ~$706, implying roughly 190% upside from the current price of ~$243 over approximately 5 years.
The mid-case assumptions require a revenue CAGR of around 9% and a net income margin of 2%, which compares to the current trailing net income margin of 1.7%.
The Q1 2026 results are consistent with those model assumptions: revenue growth of 23% YoY is well above the model’s required CAGR, and while EPS declined year over year, management confirmed the 2028 margin pathway remains intact.
The investment case is neither stronger nor weaker after Q1: it is exactly on the trajectory management laid out at June 2025 Investor Day, which means the valuation gap is real only if the 2028 margin recovery materializes.
Whether Humana stock is worth buying today hinges on a single question: can management execute the pricing and benefit adjustments needed to reach at least 3% individual MA margin by 2028 without losing enough membership to undermine the premium revenue base?
Thesis Intact Case
- Q1 2026 membership performing in line with or ahead of internal expectations across all key indicators (risk scores, APTs, pharmacy, initial claims), per Mellet on the Q1 2026 earnings call
- Operating cost initiatives on track: early retirement program exits complete by Q2 2026, outsourcing expansions advancing in finance and HR toward industry benchmarks
- Stars performance metric tracking toward top-quartile BY 2028, with HEDIS gap closure running approximately 5% ahead of last year’s pace on a per-member basis as of Q1 end, per Rechtin
- CMS improved rate notice provides a more stable funding baseline for 2027 bid planning, with management noting the rate improvement as a positive input, even while confirming the funding-trend gap remains
Thesis at Risk Case
- The funding-versus-medical-cost-trend gap is explicitly larger for the 2027 bid cycle than it was for 2026, per Rechtin, meaning benefit reductions must be deeper to hold the same margin trajectory
- IBNR reserves grew 35% sequentially in Q1 2026, well above the 22% membership growth, reflecting management’s own stated conservatism about how early it is in the year
- Welsh Carson put options could require $1B to $1.5B in cash in 2027 if exercised, adding funding pressure at precisely the moment balance sheet flexibility is most needed
- Stars thresholds for BY 2028 are unknown, and while internal progress metrics are positive, Rechtin explicitly said the outcome in October cannot be guaranteed
Should You Invest in Humana Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up HUM stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Humana Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze HUM stock on TIKR for Free →
